Evolent Health price target raised to $45 from $40 at BTIG

BTIG analyst David Larsen raised the firm’s price target on Evolent Health (EVH) to $45 from $40 and keeps a Buy rating on the shares. The company’s Q4 results were "excellent", with higher than expected revenue and adjusted EBITDA, the analyst tells investors in a research note. BTIG adds that it is positive on Evolent’s Humana (HUM) relationship and the "massive in-sell potential" into Humana for over 30 additional states.